pharma r&d market

The pharmaceutical R&D process is undergoing a monumental shift. Two-thirds of all new medicines approved at the FDA now originate from emerging and innovative biotech companies such as Reglagene.  Pharmaceutical companies have shifted away from reliance on internal R&D to licensing the products for their pipelines from the innovators. Nowhere is this truer than in the competitive oncology market. Cancer will soon pass heart disease as the number one killer on the planet. The oncology therapeutics sector is the largest by product sales, the fastest growing, and will eclipse $200 billion in annual sales by 2022. Consequently, the licensing market in the oncology sector is white hot. The competition for new oncology medicines that work in new ways is making early licensing more attractive. 

Reglagene is a Portfolio Company of Tucsons Desert Angels, Cancer Fund, and Viva BioInnovator

Desert Angels logo.jpg
viva-biotech.jpg
Reglagene has Received Grants from the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, the Flinn Foundation, and the Arizona Commerce Authority
CancerFundMore-01.png
NCI.png
Flinn Foundation.png
NINDS.png
ACA.png

CONTACT US TO
LEARN MORE

Thanks! Message sent.

1703 E Mabel St  |  Tucson,  AZ  85721  |   USA